SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Other Events
Item 8.01. Other Events.
On March 20, 2017, Sorrento Therapeutics, Inc. issued the press
release attached as Exhibit 99.1 to this Current Report on Form
8-K regarding its mutual understanding and resolution with
respect to claims by Wildcat Capital Management LLC.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Press release, dated March 20, 2017. |
About SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE)
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Recent Trading Information
SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) closed its last trading session 00.00 at 4.25 with 421,503 shares trading hands.